Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181273 | 0.85 | APP (1.00) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12973259 | 0.84 | APP (1.00) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14705443 | 0.83 | APP (0.95) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL13446070 | 0.83 | APP (0.95) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9430000 | 0.82 | HDAC6 (0.55) | APPALDH1A1KDM4EIKBKBCYP3A4 | |
| SCHEMBL14705615 | 0.81 | APP (0.91) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12973226 | 0.78 | APP (0.83) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1105472 | 0.78 | APP (0.76) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL11522028 | 0.78 | APP (0.83) | APPALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9429302 | 0.77 | APP (0.50) | APPALDH1A1KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| EP-3990112-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI International (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114269719-A | Urea derivatives as CB1 allosteric modulators | RTI国际 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3524244-A1 | BENZOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS | Icahn School of Medicine at Mount Sinai (US) | 2019-08-14 | — | — | EP | disclosed |
| CN-108299964-A | Anti-aging coating of insulation for outdoor box switchyard and preparation method thereof | 河南龙翔电气股份有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-106373641-B | Times bulky cables and preparation method thereof | 河南开启电力实业有限公司 | 2017-12-05 | — | — | CN | disclosed |
| US-5328907-A | Treatment of allograft rejection in mammals and antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1994-07-12 | — | — | US | disclosed |
| US-5108999-A | For treating inflammation, autoimmune disease or allograft rejection in mammals | SYNTEX (U.S.A.) INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0440503-A1 | 4-Isoxazolecarboxamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1991-08-07 | — | — | EP | disclosed |
| US-5001124-A | 4-isoxazolecarboxamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR119 | APP 4016/4885ALDH1A1 1661/4885KDM4E 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.